RTTNews | Jul 12, 2021 09:20AM EDT

09:19 Monday, July 12, 2021 (RTTNews.com) - GlycoMimetics Inc. (GLYC) announced that clinicians at University of California Davis Comprehensive Cancer Center initiated dosing of the first patient in a clinical study of uproleselan combined with venetoclax and azacitidine for the treatment of older or unfit patients with treatment-nave acute myeloid leukemia or AML.

The goal of the two-part trial is first to determine a recommended Phase 2 dose, and then to explore efficacy in a dose expansion cohort. Up to 31 patients will be enrolled, and a preliminary/interim readout is expected in 2022.

A preclinical study of uproleselan in combination with venetoclax and the hypomethylating agent or HMA azacitidine had demonstrated the triple combination's potential in overcoming some of the limitations related to depth and durability of response with venetoclax/HMA alone.

An oral presentation had highlighted how antagonizing E-selectin with uproleselan can overcome microenvironment-mediated resistance to venetoclax/HMA therapy. In the study, the addition of uproleselan both prolonged survival of the murine model, and also promoted normal hematopeoic stem cell pro-survival signaling.

Read the original article on RTTNews ( https://www.rttnews.com/3208397/glycomimetics-announces-initiation-of-clinical-trial-on-acute-myeloid-leukemia.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved